共 310 条
[31]
Mosca M(2018)Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3) Br J Dermatol 29 663-670
[32]
Hong J(2015)Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis J Eur Acad Dermatol Venereol 10 225-231
[33]
Brownstone N(2020)Ixekizumab and ustekinumab efficacy in nail psoriasis in patients with moderate-to-severe psoriasis: 52-week results from a phase 3, head-to-head study (IXORA-S) Dermatol Ther (Heidelb). 81 954-966
[34]
Bhutani T(2022)Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial Ann Rheum Dis 181 79-87.e1
[35]
Liao W(2019)Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial Br J Dermatol 77 242-252
[36]
Poulin Y(2017)Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis J Am Acad Dermatol 39 398-407
[37]
Crowley JJ(2012)Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial J Dermatol 170 162-168
[38]
Langley RG(2014)Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1 Br J Dermatol 24 755-756
[39]
Unnebrink K(2013)Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study J Dermatolog Treat 40 469-473
[40]
Goldblum OM(2013)Treatment of nail psoriasis with tumor necrosis factor-alpha blocker agents: an open-label, unblinded, comparative study J Dermatol 13 625-629